These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26515981)

  • 1. Advancing cell wall inhibitors towards clinical applications.
    Maffioli SI; Cruz JC; Monciardini P; Sosio M; Donadio S
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):177-84. PubMed ID: 26515981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docking on Lipid II-A Widespread Mechanism for Potent Bactericidal Activities of Antibiotic Peptides.
    Grein F; Schneider T; Sahl HG
    J Mol Biol; 2019 Aug; 431(18):3520-3530. PubMed ID: 31100388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial mechanism of lantibiotics.
    Islam MR; Nagao J; Zendo T; Sonomoto K
    Biochem Soc Trans; 2012 Dec; 40(6):1528-33. PubMed ID: 23176511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding role of lipid II as a target for lantibiotics.
    Martin NI; Breukink E
    Future Microbiol; 2007 Oct; 2(5):513-25. PubMed ID: 17927474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid II as a target for antibiotics.
    Breukink E; de Kruijff B
    Nat Rev Drug Discov; 2006 Apr; 5(4):321-32. PubMed ID: 16531990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate analogues to study cell-wall biosynthesis and its inhibition.
    Lazar K; Walker S
    Curr Opin Chem Biol; 2002 Dec; 6(6):786-93. PubMed ID: 12470732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microtiter plate bioassay to monitor the interference of antibiotics with the lipid II cycle essential for peptidoglycan biosynthesis.
    Burkard M; Stein T
    J Microbiol Methods; 2008 Sep; 75(1):70-4. PubMed ID: 18558445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II.
    Hasper HE; Kramer NE; Smith JL; Hillman JD; Zachariah C; Kuipers OP; de Kruijff B; Breukink E
    Science; 2006 Sep; 313(5793):1636-7. PubMed ID: 16973881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics.
    de Kruijff B; van Dam V; Breukink E
    Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):117-21. PubMed ID: 19008088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-resistance mechanisms of actinomycetes producing lipid II-targeting antibiotics.
    Stegmann E; Frasch HJ; Kilian R; Pozzi R
    Int J Med Microbiol; 2015 Feb; 305(2):190-5. PubMed ID: 25601631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif.
    Böttiger T; Schneider T; Martínez B; Sahl HG; Wiedemann I
    Appl Environ Microbiol; 2009 Jul; 75(13):4427-34. PubMed ID: 19429551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid II-based antimicrobial activity of the lantibiotic plantaricin C.
    Wiedemann I; Böttiger T; Bonelli RR; Schneider T; Sahl HG; Martínez B
    Appl Environ Microbiol; 2006 Apr; 72(4):2809-14. PubMed ID: 16597986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II.
    Wiedemann I; Böttiger T; Bonelli RR; Wiese A; Hagge SO; Gutsmann T; Seydel U; Deegan L; Hill C; Ross P; Sahl HG
    Mol Microbiol; 2006 Jul; 61(2):285-96. PubMed ID: 16771847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of colicin M and its orthologs targeting bacterial cell wall peptidoglycan biosynthesis.
    Barreteau H; El Ghachi M; Barnéoud-Arnoulet A; Sacco E; Touzé T; Duché D; Gérard F; Brooks M; Patin D; Bouhss A; Blanot D; van Tilbeurgh H; Arthur M; Lloubès R; Mengin-Lecreulx D
    Microb Drug Resist; 2012 Jun; 18(3):222-9. PubMed ID: 22432709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II) lantibiotic.
    Islam MR; Nishie M; Nagao J; Zendo T; Keller S; Nakayama J; Kohda D; Sahl HG; Sonomoto K
    J Am Chem Soc; 2012 Feb; 134(8):3687-90. PubMed ID: 22329487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hit 'em where it hurts: The growing and structurally diverse family of peptides that target lipid-II.
    Oppedijk SF; Martin NI; Breukink E
    Biochim Biophys Acta; 2016 May; 1858(5):947-57. PubMed ID: 26523408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo cluster formation of nisin and lipid II is correlated with membrane depolarization.
    Tol MB; Morales Angeles D; Scheffers DJ
    Antimicrob Agents Chemother; 2015; 59(6):3683-6. PubMed ID: 25870072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lesson in efficient killing from two-component lantibiotics.
    Breukink E
    Mol Microbiol; 2006 Jul; 61(2):271-3. PubMed ID: 16771845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting bactoprenol-coupled cell envelope precursors.
    Ulm H; Schneider T
    Appl Microbiol Biotechnol; 2016 Sep; 100(18):7815-25. PubMed ID: 27495122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid II and other bactoprenol-bound cell wall precursors as drug targets.
    Schneider T; Sahl HG
    Curr Opin Investig Drugs; 2010 Feb; 11(2):157-64. PubMed ID: 20112165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.